 | • レポートコード：GIR-107A12638 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、放射免疫療法のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。放射免疫療法の種類別市場規模（非ホジキンリンパ腫（NHL）、濾胞性リンパ腫、固形腫瘍、乳がん、卵巣がん、骨肉腫、神経芽細胞腫、前立腺がん）、用途別市場規模（腫瘍抗原、放射性核種、抗体）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・放射免疫療法の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Bayer Healthcare Pharmaceuticals、BioSynthema、Clarity Pharmaceuticals、Curasight、Endocyte、Immunomedics、Molecular Insight Pharmaceuticals、Nordic Nanovector、PDL Biopharma、Philogen、RadioMedix、Stella Pharma、Telix Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：非ホジキンリンパ腫（NHL）、濾胞性リンパ腫、固形腫瘍、乳がん、卵巣がん、骨肉腫、神経芽細胞腫、前立腺がん ・用途別分析2016年-2026年：腫瘍抗原、放射性核種、抗体 ・放射免疫療法の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・放射免疫療法のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・放射免疫療法のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・放射免疫療法の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・放射免疫療法の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Radioimmunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Radioimmunotherapy size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Radioimmunotherapy market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Radioimmunotherapy market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Non Hodgkin Lymphoma (NHL)
Follicular Lymphoma
Solid Tumors
Breast Cancer
Ovarian Cancer
Osteosarcoma
Neuroblastoma
Prostate Cancer
Market segment by Application, can be divided into
Tumor Antigens
Radionuclides
Antibodies
Market segment by players, this report covers
Bayer Healthcare Pharmaceuticals
BioSynthema
Clarity Pharmaceuticals
Curasight
Endocyte
Immunomedics
Molecular Insight Pharmaceuticals
Nordic Nanovector
PDL Biopharma
Philogen
RadioMedix
Stella Pharma
Telix Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Radioimmunotherapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Radioimmunotherapy, with revenue, gross margin and global market share of Radioimmunotherapy from 2019 to 2021.
Chapter 3, the Radioimmunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Radioimmunotherapy market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Radioimmunotherapy research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Radioimmunotherapy
1.2 Classification of Radioimmunotherapy by Type
1.2.1 Overview: Global Radioimmunotherapy Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Radioimmunotherapy Revenue Market Share by Type in 2020
1.2.3 Non Hodgkin Lymphoma (NHL)
1.2.4 Follicular Lymphoma
1.2.5 Solid Tumors
1.2.6 Breast Cancer
1.2.7 Ovarian Cancer
1.2.8 Osteosarcoma
1.2.9 Neuroblastoma
1.2.10 Prostate Cancer
1.3 Global Radioimmunotherapy Market by Application
1.3.1 Overview: Global Radioimmunotherapy Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Tumor Antigens
1.3.3 Radionuclides
1.3.4 Antibodies
1.4 Global Radioimmunotherapy Market Size & Forecast
1.5 Global Radioimmunotherapy Market Size and Forecast by Region
1.5.1 Global Radioimmunotherapy Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Radioimmunotherapy Market Size by Region, (2016-2021)
1.5.3 North America Radioimmunotherapy Market Size and Prospect (2016-2026)
1.5.4 Europe Radioimmunotherapy Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Radioimmunotherapy Market Size and Prospect (2016-2026)
1.5.6 South America Radioimmunotherapy Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Radioimmunotherapy Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Radioimmunotherapy Market Drivers
1.6.2 Radioimmunotherapy Market Restraints
1.6.3 Radioimmunotherapy Trends Analysis
2 Company Profiles
2.1 Bayer Healthcare Pharmaceuticals
2.1.1 Bayer Healthcare Pharmaceuticals Details
2.1.2 Bayer Healthcare Pharmaceuticals Major Business
2.1.3 Bayer Healthcare Pharmaceuticals Radioimmunotherapy Product and Solutions
2.1.4 Bayer Healthcare Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Bayer Healthcare Pharmaceuticals Recent Developments and Future Plans
2.2 BioSynthema
2.2.1 BioSynthema Details
2.2.2 BioSynthema Major Business
2.2.3 BioSynthema Radioimmunotherapy Product and Solutions
2.2.4 BioSynthema Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 BioSynthema Recent Developments and Future Plans
2.3 Clarity Pharmaceuticals
2.3.1 Clarity Pharmaceuticals Details
2.3.2 Clarity Pharmaceuticals Major Business
2.3.3 Clarity Pharmaceuticals Radioimmunotherapy Product and Solutions
2.3.4 Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Clarity Pharmaceuticals Recent Developments and Future Plans
2.4 Curasight
2.4.1 Curasight Details
2.4.2 Curasight Major Business
2.4.3 Curasight Radioimmunotherapy Product and Solutions
2.4.4 Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Curasight Recent Developments and Future Plans
2.5 Endocyte
2.5.1 Endocyte Details
2.5.2 Endocyte Major Business
2.5.3 Endocyte Radioimmunotherapy Product and Solutions
2.5.4 Endocyte Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Endocyte Recent Developments and Future Plans
2.6 Immunomedics
2.6.1 Immunomedics Details
2.6.2 Immunomedics Major Business
2.6.3 Immunomedics Radioimmunotherapy Product and Solutions
2.6.4 Immunomedics Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Immunomedics Recent Developments and Future Plans
2.7 Molecular Insight Pharmaceuticals
2.7.1 Molecular Insight Pharmaceuticals Details
2.7.2 Molecular Insight Pharmaceuticals Major Business
2.7.3 Molecular Insight Pharmaceuticals Radioimmunotherapy Product and Solutions
2.7.4 Molecular Insight Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Molecular Insight Pharmaceuticals Recent Developments and Future Plans
2.8 Nordic Nanovector
2.8.1 Nordic Nanovector Details
2.8.2 Nordic Nanovector Major Business
2.8.3 Nordic Nanovector Radioimmunotherapy Product and Solutions
2.8.4 Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Nordic Nanovector Recent Developments and Future Plans
2.9 PDL Biopharma
2.9.1 PDL Biopharma Details
2.9.2 PDL Biopharma Major Business
2.9.3 PDL Biopharma Radioimmunotherapy Product and Solutions
2.9.4 PDL Biopharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 PDL Biopharma Recent Developments and Future Plans
2.10 Philogen
2.10.1 Philogen Details
2.10.2 Philogen Major Business
2.10.3 Philogen Radioimmunotherapy Product and Solutions
2.10.4 Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Philogen Recent Developments and Future Plans
2.11 RadioMedix
2.11.1 RadioMedix Details
2.11.2 RadioMedix Major Business
2.11.3 RadioMedix Radioimmunotherapy Product and Solutions
2.11.4 RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 RadioMedix Recent Developments and Future Plans
2.12 Stella Pharma
2.12.1 Stella Pharma Details
2.12.2 Stella Pharma Major Business
2.12.3 Stella Pharma Radioimmunotherapy Product and Solutions
2.12.4 Stella Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Stella Pharma Recent Developments and Future Plans
2.13 Telix Pharmaceuticals
2.13.1 Telix Pharmaceuticals Details
2.13.2 Telix Pharmaceuticals Major Business
2.13.3 Telix Pharmaceuticals Radioimmunotherapy Product and Solutions
2.13.4 Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Telix Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Radioimmunotherapy Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Radioimmunotherapy Players Market Share
3.2.2 Top 10 Radioimmunotherapy Players Market Share
3.2.3 Market Competition Trend
3.3 Radioimmunotherapy Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Radioimmunotherapy Revenue and Market Share by Type (2016-2021)
4.2 Global Radioimmunotherapy Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Radioimmunotherapy Revenue Market Share by Application (2016-2021)
5.2 Radioimmunotherapy Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Radioimmunotherapy Revenue by Type (2016-2026)
6.2 North America Radioimmunotherapy Revenue by Application (2016-2026)
6.3 North America Radioimmunotherapy Market Size by Country
6.3.1 North America Radioimmunotherapy Revenue by Country (2016-2026)
6.3.2 United States Radioimmunotherapy Market Size and Forecast (2016-2026)
6.3.3 Canada Radioimmunotherapy Market Size and Forecast (2016-2026)
6.3.4 Mexico Radioimmunotherapy Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Radioimmunotherapy Revenue by Type (2016-2026)
7.2 Europe Radioimmunotherapy Revenue by Application (2016-2026)
7.3 Europe Radioimmunotherapy Market Size by Country
7.3.1 Europe Radioimmunotherapy Revenue by Country (2016-2026)
7.3.2 Germany Radioimmunotherapy Market Size and Forecast (2016-2026)
7.3.3 France Radioimmunotherapy Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Radioimmunotherapy Market Size and Forecast (2016-2026)
7.3.5 Russia Radioimmunotherapy Market Size and Forecast (2016-2026)
7.3.6 Italy Radioimmunotherapy Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Radioimmunotherapy Revenue by Type (2016-2026)
8.2 Asia-Pacific Radioimmunotherapy Revenue by Application (2016-2026)
8.3 Asia-Pacific Radioimmunotherapy Market Size by Region
8.3.1 Asia-Pacific Radioimmunotherapy Revenue by Region (2016-2026)
8.3.2 China Radioimmunotherapy Market Size and Forecast (2016-2026)
8.3.3 Japan Radioimmunotherapy Market Size and Forecast (2016-2026)
8.3.4 South Korea Radioimmunotherapy Market Size and Forecast (2016-2026)
8.3.5 India Radioimmunotherapy Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Radioimmunotherapy Market Size and Forecast (2016-2026)
8.3.7 Australia Radioimmunotherapy Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Radioimmunotherapy Revenue by Type (2016-2026)
9.2 South America Radioimmunotherapy Revenue by Application (2016-2026)
9.3 South America Radioimmunotherapy Market Size by Country
9.3.1 South America Radioimmunotherapy Revenue by Country (2016-2026)
9.3.2 Brazil Radioimmunotherapy Market Size and Forecast (2016-2026)
9.3.3 Argentina Radioimmunotherapy Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Radioimmunotherapy Revenue by Type (2016-2026)
10.2 Middle East & Africa Radioimmunotherapy Revenue by Application (2016-2026)
10.3 Middle East & Africa Radioimmunotherapy Market Size by Country
10.3.1 Middle East & Africa Radioimmunotherapy Revenue by Country (2016-2026)
10.3.2 Turkey Radioimmunotherapy Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Radioimmunotherapy Market Size and Forecast (2016-2026)
10.3.4 UAE Radioimmunotherapy Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Radioimmunotherapy Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Radioimmunotherapy Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Radioimmunotherapy Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Radioimmunotherapy Revenue (USD Million) by Region (2016-2021)
Table 5. Global Radioimmunotherapy Revenue Market Share by Region (2021-2026)
Table 6. Bayer Healthcare Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Bayer Healthcare Pharmaceuticals Major Business
Table 8. Bayer Healthcare Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 9. Bayer Healthcare Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. BioSynthema Corporate Information, Head Office, and Major Competitors
Table 11. BioSynthema Major Business
Table 12. BioSynthema Radioimmunotherapy Product and Solutions
Table 13. BioSynthema Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Clarity Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 15. Clarity Pharmaceuticals Major Business
Table 16. Clarity Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 17. Clarity Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Curasight Corporate Information, Head Office, and Major Competitors
Table 19. Curasight Major Business
Table 20. Curasight Radioimmunotherapy Product and Solutions
Table 21. Curasight Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Endocyte Corporate Information, Head Office, and Major Competitors
Table 23. Endocyte Major Business
Table 24. Endocyte Radioimmunotherapy Product and Solutions
Table 25. Endocyte Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Immunomedics Corporate Information, Head Office, and Major Competitors
Table 27. Immunomedics Major Business
Table 28. Immunomedics Radioimmunotherapy Product and Solutions
Table 29. Immunomedics Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Molecular Insight Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Molecular Insight Pharmaceuticals Major Business
Table 32. Molecular Insight Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 33. Molecular Insight Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Nordic Nanovector Corporate Information, Head Office, and Major Competitors
Table 35. Nordic Nanovector Major Business
Table 36. Nordic Nanovector Radioimmunotherapy Product and Solutions
Table 37. Nordic Nanovector Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. PDL Biopharma Corporate Information, Head Office, and Major Competitors
Table 39. PDL Biopharma Major Business
Table 40. PDL Biopharma Radioimmunotherapy Product and Solutions
Table 41. PDL Biopharma Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Philogen Corporate Information, Head Office, and Major Competitors
Table 43. Philogen Major Business
Table 44. Philogen Radioimmunotherapy Product and Solutions
Table 45. Philogen Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. RadioMedix Corporate Information, Head Office, and Major Competitors
Table 47. RadioMedix Major Business
Table 48. RadioMedix Radioimmunotherapy Product and Solutions
Table 49. RadioMedix Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Stella Pharma Corporate Information, Head Office, and Major Competitors
Table 51. Stella Pharma Major Business
Table 52. Stella Pharma Radioimmunotherapy Product and Solutions
Table 53. Stella Pharma Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Telix Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 55. Telix Pharmaceuticals Major Business
Table 56. Telix Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 57. Telix Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Global Radioimmunotherapy Revenue (USD Million) by Players (2019-2021)
Table 59. Global Radioimmunotherapy Revenue Share by Players (2019-2021)
Table 60. Breakdown of Radioimmunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Radioimmunotherapy Players Head Office, Products and Services Provided
Table 62. Radioimmunotherapy Mergers & Acquisitions in the Past Five Years
Table 63. Radioimmunotherapy New Entrants and Expansion Plans
Table 64. Global Radioimmunotherapy Revenue (USD Million) by Type (2016-2021)
Table 65. Global Radioimmunotherapy Revenue Share by Type (2016-2021)
Table 66. Global Radioimmunotherapy Revenue Forecast by Type (2021-2026)
Table 67. Global Radioimmunotherapy Revenue by Application (2016-2021)
Table 68. Global Radioimmunotherapy Revenue Forecast by Application (2021-2026)
Table 69. North America Radioimmunotherapy Revenue by Type (2016-2021) & (USD Million)
Table 70. North America Radioimmunotherapy Revenue by Type (2021-2026) & (USD Million)
Table 71. North America Radioimmunotherapy Revenue by Application (2016-2021) & (USD Million)
Table 72. North America Radioimmunotherapy Revenue by Application (2021-2026) & (USD Million)
Table 73. North America Radioimmunotherapy Revenue by Country (2016-2021) & (USD Million)
Table 74. North America Radioimmunotherapy Revenue by Country (2021-2026) & (USD Million)
Table 75. Europe Radioimmunotherapy Revenue by Type (2016-2021) & (USD Million)
Table 76. Europe Radioimmunotherapy Revenue by Type (2021-2026) & (USD Million)
Table 77. Europe Radioimmunotherapy Revenue by Application (2016-2021) & (USD Million)
Table 78. Europe Radioimmunotherapy Revenue by Application (2021-2026) & (USD Million)
Table 79. Europe Radioimmunotherapy Revenue by Country (2016-2021) & (USD Million)
Table 80. Europe Radioimmunotherapy Revenue by Country (2021-2026) & (USD Million)
Table 81. Asia-Pacific Radioimmunotherapy Revenue by Type (2016-2021) & (USD Million)
Table 82. Asia-Pacific Radioimmunotherapy Revenue by Type (2021-2026) & (USD Million)
Table 83. Asia-Pacific Radioimmunotherapy Revenue by Application (2016-2021) & (USD Million)
Table 84. Asia-Pacific Radioimmunotherapy Revenue by Application (2021-2026) & (USD Million)
Table 85. Asia-Pacific Radioimmunotherapy Revenue by Region (2016-2021) & (USD Million)
Table 86. Asia-Pacific Radioimmunotherapy Revenue by Region (2021-2026) & (USD Million)
Table 87. South America Radioimmunotherapy Revenue by Type (2016-2021) & (USD Million)
Table 88. South America Radioimmunotherapy Revenue by Type (2021-2026) & (USD Million)
Table 89. South America Radioimmunotherapy Revenue by Application (2016-2021) & (USD Million)
Table 90. South America Radioimmunotherapy Revenue by Application (2021-2026) & (USD Million)
Table 91. South America Radioimmunotherapy Revenue by Country (2016-2021) & (USD Million)
Table 92. South America Radioimmunotherapy Revenue by Country (2021-2026) & (USD Million)
Table 93. Middle East & Africa Radioimmunotherapy Revenue by Type (2016-2021) & (USD Million)
Table 94. Middle East & Africa Radioimmunotherapy Revenue by Type (2021-2026) & (USD Million)
Table 95. Middle East & Africa Radioimmunotherapy Revenue by Application (2016-2021) & (USD Million)
Table 96. Middle East & Africa Radioimmunotherapy Revenue by Application (2021-2026) & (USD Million)
Table 97. Middle East & Africa Radioimmunotherapy Revenue by Country (2016-2021) & (USD Million)
Table 98. Middle East & Africa Radioimmunotherapy Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Radioimmunotherapy Picture
Figure 2. Global Radioimmunotherapy Revenue Market Share by Type in 2020
Figure 3. Non Hodgkin Lymphoma (NHL)
Figure 4. Follicular Lymphoma
Figure 5. Solid Tumors
Figure 6. Breast Cancer
Figure 7. Ovarian Cancer
Figure 8. Osteosarcoma
Figure 9. Neuroblastoma
Figure 10. Prostate Cancer
Figure 11. Radioimmunotherapy Revenue Market Share by Application in 2020
Figure 12. Tumor Antigens Picture
Figure 13. Radionuclides Picture
Figure 14. Antibodies Picture
Figure 15. Global Radioimmunotherapy Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global Radioimmunotherapy Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global Radioimmunotherapy Revenue Market Share by Region (2016-2026)
Figure 18. Global Radioimmunotherapy Revenue Market Share by Region in 2020
Figure 19. North America Radioimmunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe Radioimmunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific Radioimmunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America Radioimmunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Middle East and Africa Radioimmunotherapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. Radioimmunotherapy Market Drivers
Figure 25. Radioimmunotherapy Market Restraints
Figure 26. Radioimmunotherapy Market Trends
Figure 27. Bayer Healthcare Pharmaceuticals Recent Developments and Future Plans
Figure 28. BioSynthema Recent Developments and Future Plans
Figure 29. Clarity Pharmaceuticals Recent Developments and Future Plans
Figure 30. Curasight Recent Developments and Future Plans
Figure 31. Endocyte Recent Developments and Future Plans
Figure 32. Immunomedics Recent Developments and Future Plans
Figure 33. Molecular Insight Pharmaceuticals Recent Developments and Future Plans
Figure 34. Nordic Nanovector Recent Developments and Future Plans
Figure 35. PDL Biopharma Recent Developments and Future Plans
Figure 36. Philogen Recent Developments and Future Plans
Figure 37. RadioMedix Recent Developments and Future Plans
Figure 38. Stella Pharma Recent Developments and Future Plans
Figure 39. Telix Pharmaceuticals Recent Developments and Future Plans
Figure 40. Global Radioimmunotherapy Revenue Share by Players in 2020
Figure 41. Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 42. Global Top 3 Players Radioimmunotherapy Revenue Market Share in 2020
Figure 43. Global Top 10 Players Radioimmunotherapy Revenue Market Share in 2020
Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 45. Global Radioimmunotherapy Revenue Share by Type in 2020
Figure 46. Global Radioimmunotherapy Market Share Forecast by Type (2021-2026)
Figure 47. Global Radioimmunotherapy Revenue Share by Application in 2020
Figure 48. Global Radioimmunotherapy Market Share Forecast by Application (2021-2026)
Figure 49. North America Radioimmunotherapy Sales Market Share by Type (2016-2026)
Figure 50. North America Radioimmunotherapy Sales Market Share by Application (2016-2026)
Figure 51. North America Radioimmunotherapy Revenue Market Share by Country (2016-2026)
Figure 52. United States Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Canada Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Mexico Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Europe Radioimmunotherapy Sales Market Share by Type (2016-2026)
Figure 56. Europe Radioimmunotherapy Sales Market Share by Application (2016-2026)
Figure 57. Europe Radioimmunotherapy Revenue Market Share by Country (2016-2026)
Figure 58. Germany Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. France Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. United Kingdom Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Russia Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Italy Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Asia-Pacific Radioimmunotherapy Sales Market Share by Type (2016-2026)
Figure 64. Asia-Pacific Radioimmunotherapy Sales Market Share by Application (2016-2026)
Figure 65. Asia-Pacific Radioimmunotherapy Revenue Market Share by Region (2016-2026)
Figure 66. China Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Japan Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South Korea Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. India Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Southeast Asia Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Australia Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South America Radioimmunotherapy Sales Market Share by Type (2016-2026)
Figure 73. South America Radioimmunotherapy Sales Market Share by Application (2016-2026)
Figure 74. South America Radioimmunotherapy Revenue Market Share by Country (2016-2026)
Figure 75. Brazil Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Argentina Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Middle East and Africa Radioimmunotherapy Sales Market Share by Type (2016-2026)
Figure 78. Middle East and Africa Radioimmunotherapy Sales Market Share by Application (2016-2026)
Figure 79. Middle East and Africa Radioimmunotherapy Revenue Market Share by Country (2016-2026)
Figure 80. Turkey Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Saudi Arabia Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. UAE Radioimmunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Methodology
Figure 84. Research Process and Data Source
世界の前立腺がん診断市場 2021：企業別、地域別、種類・用途別 The Prostate Cancer Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…- 世界の乳がん用CDK4/6阻害薬市場 2021：企業別、地域別、種類・用途別 The CDK4/6 Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…
- 世界の前立腺がん治療薬市場 2021：企業別、地域別、種類・用途別 The Prostate Cancer Medicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- 世界の乳がん用HER-2標的薬市場 2021：企業別、地域別、種類・用途別 The HER-2 Targeted Drugs for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…
- 世界の未分化リンパ腫キナーゼ阻害剤市場 2021：企業別、地域別、種類・用途別 The Anaplastic Lymphoma Kinase Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization,…